NYXH News & Events

Reports Q4 revenue EUR 5.64M vs. EUR 1.26M last year. "The fourth quarter marked our first full quarter of U.S. commercialization, and we are very pleased with the strong momentum we generated which led to us exceeding our revenue expectations for the quarter," commented Olivier Taelman, Nyxoah's CEO. "The feedback from surgeons and their patients has been positive and these procedures have been consistently reimbursed by major commercial payors and Medicare to date. We are excited about the opportunity in front of us and feel confident we will deliver significant growth going forward."

The company said, "We expect U.S. net revenue for the first quarter of 2026 to grow by approximately 25% over the fourth quarter of 2025 and expect net revenue for the second quarter of 2026 to grow by approximately 25% over the first quarter of 2026. International revenue is expected to follow a typical seasonal pattern."